Breast cancer cell line toxicity of a flavonoid isolated from *Baccharis densiflora*

Wendy Soria Sotillo, Santiago Tarqui, Xiaoli Huang, Giovanna Almanza and Stina Oredsson*

**Abstract**

**Background:** Flavonoids are compounds of interest in the search for new anti-cancer therapies. We have previously isolated the methoxyflavones 5,4'-dihydroxy-6,7,8,3'-tetramethoxyflavone (8-methoxycirsilineol), 5,4'-dihydroxy-6,7,8-trimethoxyflavone (xanthomicrol), and 5,4',3'-trihydroxy-6,7,8-trimethoxyflavone (sideritoflavone) from *Baccharis densiflora*. Herein, we investigate the toxicity of these methoxyflavones in human breast-derived cell line. Our main aim was to focus on the cancer stem cell (CSC) sub-population of JIMT-1 breast cancer cells.

**Methods:** Initially, dose response experiments yielding inhibitory concentration 50 (IC₅₀) values were performed using MCF-7, HCC1937, and JIMT-1 breast cancer, and the MCF-10A normal-like breast cell lines to get an understanding of toxic ranges. Due to a clear difference in the toxicity of the flavones, only sideritoflavone was selected for further studies using the JIMT-1 cell line. Effects on the CSC sub-population was investigated using flow cytometry-based methods. A wound healing assay and digital holographic microscopy were used to investigate effects on cell movement. A reporter assay was used to study effects on signal transduction pathways and Western blot for protein expression.

**Results:** The dose response data showed that 8-methoxycirsilineol was non-toxic at concentrations below 100 μM, that the IC₅₀ of xanthomicrol was between 50 and 100 μM, while sideritoflavone was highly toxic with a single digit μM IC₅₀ in all cell lines. Treatment of the JIMT-1 cells with 2 μM sideritoflavone did not selectively effect the CSC sub-population. Instead, sideritoflavone treatment inhibited the proliferation of both the non-CSC and the CSC sub-populations to the same extent. The inhibition of cell proliferation resulted in an accumulation of cells in the G₂ phase of the cell cycle and the treated cells showed an increased level of γ-H2A histone family member X indicating DNA double strand breaks. Analysis of the effect of sideritoflavone treatment on signal transduction pathways showed activation of the Wnt, Myc/Max, and transforming growth factor-β pathways. The level of p65/nuclear factor kappa-light-chain-enhancer of activated B cells was increased in sideritoflavone-treated cells. Cell movement was decreased by sideritoflavone treatment.

**Conclusions:** Altogether our data show that the methoxyflavone sideritoflavone has favourable anti-cancer effects that may be exploited for development to be used in combination with CSC specific compounds.

**Keywords:** Flavonoids, Sideritoflavone, Breast cancer, Cytotoxicity, Cell cycle, Cell movement, Cancer stem cells

**Background**

Breast cancer is the most common cancer in women worldwide and in 2018 approximately 2 million new cases were reported [1]. Much effort is put into finding sources of new unique compounds that can be used on their own, in combinations, and for synthesis of compounds with higher bioactivity. A group of compounds of interest in the search for new anti-cancer therapy is flavonoids [2]. These plant-based secondary metabolites are categorized into flavonols, flavones, catechins,

---

* Correspondence: stina.oredsson@biol.lu.se  
  1Department of Biology, Lund University, Lund, Sweden  
  Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
flavanones are powerful antioxidants with anti-inflammatory and immune system benefits and based on these data, the anti-cancer properties of the compounds have become a new field of interest. Recent studies also suggest that the consumption of different fruits and vegetables decreases the cancer risk level at least by 20% [2, 3], presumably due to their antioxidant properties. However, available evidence from cell culture experiments suggests that many biological effects of flavonoids are related to their ability to modulate cell signalling pathways [4]. Flavonoids have been associated with effects on gene expression, mutagenesis, carcinogenesis, and cell death. They can intercalate in the DNA duplex and react with free radicals in order to protect DNA from oxidative damage [5].

The Baccharis genus has been reported as a plant group with several therapeutic properties [6]. Among them, the anti-inflammatory activity is correlated with the level of flavonoids found in the plants. A survey of current available chemical data suggests that flavonoids such as methylated flavones, and to a lesser extent flavonols, mainly aglycones, are the main classes of phenolic compounds that can be found in Baccharis spp. [7, 8]. Here we investigated the anticancer properties of three flavones isolated from Baccharis densiflora, previously identified as Baccharis pentlandii [7], a shrub used in Bolivia for the treatment of rheumatic diseases, sprains, broken bones, and dislocations [9].

Human cancer-derived cell lines are fundamental models used in laboratories to study the biology of cancer and to perform pre-clinical testing of new potential anti-cancer agents. The use of cancer cell lines is essential for the development of new anti-cancer drugs, understanding their mechanisms of action, the resistance/sensitivity patterns of chemotherapeutics already used in cancer treatment, and the development of more targeted anti-cancer drugs [10]. Human breast cancer cell lines maintain some of the phenotypic and genotypic heterogeneities seen in a tumour [11]. In breast tumours and also in a majority of other cancer types, a rare subpopulation of cancer cells that has the ability to form new phenotypically and genotypically identical tumours at distant sites has been identified [12]. These cells have been coined tumour initiating cells or cancer stem cells (CSCs) [13]. In breast cancer, the CSCs are identified based on different markers and properties of the cells [14, 15]. Targeting of CSCs has been suggested to be important in cancer cure even though they may just be a fraction of the bulk of cancer cells in a tumour.

Herein, we investigated how three methoxyflavonones isolated from B. densiflora affect bulk cancer cell properties such as cell proliferation and cell migration but also CSC specific properties. Only one of the flavones was active at a single digit μM inhibitory concentration 50 (IC₅₀), while the other two had IC₅₀ values above 50 μM despite quite similar chemical structures. The active compound, the methoxyflavone sideritoflavone, inhibited cell proliferation and cell migration but the mechanism of action does not involve CSC specific effects and thus it may e.g. be combined with CSC specific compounds in new cancer treatment strategies.

Methods

Plant material

Aerial parts of B. densiflora Wedd, previously identified as Baccharis pentlandii DC., were collected on February of 2017 in Cota Cota (3422 m.a.s.l.; 16° 32’ 27” S 68° 40’ 16” W), located in the outskirts of La Paz, Bolivia. The plant was identified by Esther Valenzuela at the JBLP (Jardín Botánico del Herbario Nacional de Bolivia) where the voucher specimen is kept (code Beck St G. 2858).

Extraction and isolation of compounds

Dried leaves of B. densiflora (200 g) were crushed and macerated in 96% ethanol, in a mass-solvent ratio of 1:15, at room temperature, for 15 min. The ethanol extract was filtered and the solvent was evaporated under reduced pressure in a rota-evaporator at a temperature of 40 °C, to obtain 20.8 g of dry extract. The ethanol extract (2 g) was separated by column chromatography on Sephadex LH-20 using 96% ethanol as the mobile phase to give 5 mg of a pure flavonoid 2 (xanthemicrol) and 50 mg of a mixture of the two flavonoids 1 and 3. The mixture was subjected to preparative HPLC using a column of reverse phase C18–100* 10 mm and 5 μm with 100 μL loop. The mobile phase was a solvent mixture of 50% acetonitrile, 49.9% H2O, and 0.1% HCO2H. A solution of the flavonoid mixture at a concentration of 30 mg/ml, was separated with a flow of 2.8 ml/min for 11 min and analysed at a wavelength of 360 nm, obtaining 15 mg of sideritoflavone 3 and 10 mg of 8-methoxysirineleol 1. The compounds were identified by NMR data which were compared with bibliographic data [7, 16–18].

Compounds and stock solutions

The compounds were dissolved in 100% dimethyl sulfoxide (DMSO) at a concentration of 100 mM and kept at 4 °C. Controls were treated with the same final DMSO concentration as the DMSO concentration in treated cultures maximally at 0.1% DMSO depending on the assay and chosen concentration.

Cell lines and culture conditions

The JIMT-1 human breast carcinoma cell line (ACC589) was purchased from the German Collection of
Microorganisms and Cell Cultures (Braunschweig, Germany). The normal-like breast epithelial MCF-10A cell line (CRL-10317), the cancer cell lines MCF-7 (HTB-22) and HCC1937 (CRL-2336) were purchased from American Type Culture Collection (Manassas, VA, USA). The cells were tested negative for mycoplasma (Eurofins, Konstanz, Germany).

The JIMT-1 cells were routinely cultured at 37 °C in a humidified incubator with 5% CO₂ in air. The cells were cultured in DMEM/Ham’s F-12 medium supplemented with 10% fetal bovine serum (FBS), glutamine (2 mM), non-essential amino acids (1 mM), insulin (10 μg/ml), penicillin (100 U/ml), and streptomycin (100 μg/ml).

MCF-10A, MCF-7, and HCC1937 cell lines were cultured in RPMI 1640 medium (VWR) supplemented with 10% heat-inactivated FBS (VWR, Lund, Sweden), glutamine (2 mM), 1 mM non-essential amino acids (VWR), 10 μg/ml insulin (Sigma-Aldrich, Stockholm, Sweden), and 100 U/ml penicillin/100 μg/ml streptomycin (VWR).

The MCF-10A cells were also supplemented with 20 ng/ml epidermal growth factor (Sigma-Aldrich), 50 ng/ml cholera toxin (Sigma-Aldrich), and 250 ng/ml hydrocortisol (Sigma-Aldrich). Finally, the HCC1937 medium was supplemented with 20 ng/ml epidermal growth factor (Sigma-Aldrich) besides the mentioned supplements.

**Dose response assay**

For the dose response assay, cells were detached by trypsinization and counted in a hemocytometer. Cells were plated in 180 μl medium into 96-well flat-bottomed tissue culture plates followed by overnight incubation at 37 °C in the CO₂ incubator. Cells were incubated in the presence of the compounds for 72 h at concentrations from 0.1 to 100 μM. After 72 h of compound exposure, 20 μl of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) solution (5 mg/ml in PBS) was added to each well, and the plates were returned to the CO₂ incubator for 1 h. The medium with MTT was removed and the formazan crystals, formed by reduction in live attached cells, were dissolved in 100 μl DMSO. The plates were gently swirled at room temperature for 10 min. The absorbance was measured at 540 nm using a Multiskan™ FC microplate photometer and the software SkanIt for Multiskan FC 3.1. Ink, both from Thermo scientific (Waltham, Massachusetts USA). The results were analysed using GraphPad 6 computer software (La Jolla, California, USA). The IC₅₀ values with 95% confidence interval are based on at least 3 dose-response experiments.

**Western blot analysis**

Cells were seeded at a density of 300,000 cells in 5 ml medium in Petri dishes with 5 cm diameter. They were then incubated for 24 h to allow cell attachment. Then, sideritoflavone was added at 2 or 2.5 μM concentrations. Cells were collected 72 h later by Accutase™ (Sigma, Sweden AB) treatment, resuspended, counted, and pelleted. The dry pellets were stored at −80 °C until use. The pellets were then diluted in sample buffer (62.5 mM Tris-HCl (pH 6.8), 20% glycerol, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol, and 1% NP-40; 100,000 cells/15 μl). The samples were sonicated twice for 20 s, boiled for 7 min, and stored at −20 °C until further use. Pre-cast polyacrylamide Mini-PROTEAN™ TGX™ Precast Gels (4–20% acrylamide Bis-Tris) were loaded with 15 μl of prepared sample per lane. Western blot and electrophoresis were performed in a Bio-Rad electrophoresis and blotting system (Bio-Rad, Hercules, California, USA). Electrophoresis was performed at 150 V for 5 min and at 300 V for 15 min in a Tris-glycine buffer. Then, the gels were blotted onto nitrocellulose membranes using a semi-dry Trans-Blot™ Turbo™ Transfer System (Bio-Rad, Hercules, California, USA). The membranes were blocked in 5% bovine serum albumin (BSA) (Sigma-Aldrich, Copenhagen, Denmark) and 1% Tween 20 (Sigma-Aldrich) in PBS and incubated with primary antibodies against cyclin B1 (1:1000) (Santa Cruz Biotechnology, Texas, USA, sc-595), total p65 (1:1000) (Abcam, Cambridge, UK, ab76311), γ-H2A histone family member X (γ-H2AX) (1:1000) (Cell Signalling, Massachusetts, USA, # 2577), β-catenin (1:500) (BD Transduction laboratories™, CA, USA, 610154), or β-actin (1:500) (Abcam, Cambridge, UK). All antibodies were diluted in PBS containing 5% BSA and 0.1% Tween 20. After incubation with horseradish peroxidase (HRP)-conjugated swine anti-rabbit or HRP-conjugated goat anti-mouse secondary antibodies (Dako, Glostrup, Denmark) at room temperature, the membranes were exposed to enhanced chemiluminescent solution (GE Healthcare, Buckinghamshire, UK) to detect the protein bands. Data were collected and analysed using Quantity One software (Bio-Rad, Hercules, California, USA). The intensities of the bands were determined by densitometric scanning.

**Reporter assay for analysis of 10 signaling pathways**

The Cignal Finder Cancer 10-Pathway Reporter Array (plate format) (Qiagen, Hilden, Germany) was used to simultaneously analyse the effect of treatment with sideritoflavone on 10 signalling pathways. JIMT-1 cells (2 x 10⁴ cells) were plated in 100 μl of Opti-MEM® containing 10% FBS per well in the provided 96 well white assay plate containing reporters. After 24 h, the cells were transfected overnight using Attractene. Cells were then treated for 24 h with 2 μM sideritoflavone. Firefly and Renilla signals were detected using Dual-Glo luciferase detection reagents (Promega, Wisc., USA) according to the manufacturer’s instructions. Renilla luciferase was
used as the internal transfection control. Firefly luciferase levels were normalized to Renilla luciferase levels to generate a measurement of relative luciferase units. The results are presented as percentage luciferase activities normalized to transfected control JIMT-1 cells. The experiment was performed two times with three independent samples in each experiment.

**Scrape wound healing**
The scrape wound healing assay that determines effects on directed cell migration was performed as described by Huang et al. [19]. Sideritoflavone was added to the final concentrations of 2 or 2.5 μM.

**Phase holographic imaging**
Phase holographic imaging was used to monitor cell motility and cell proliferation. The JIMT-1 cells were seeded at a density of 135,000 cells per well in a 6-well plate. Cells were incubated for 24 h to let them attach to the bottom of the plate. Sideritoflavone was added to a concentration of 2 μM or 2.5 μM. The standard lid was replaced by HoloLid™ (71,110 PHI), and the 6-well plate placed on the motorized stage of a HoloMonitor® M4 (Phase Holographic Imaging AB (PHI), Lund, Sweden) placed in a CO₂ incubator for cell culturing. Images were acquired with the software App Suite™ 2 (PHI) at three positions per well, every 5 min for 72 h. The experiment was repeated three times with two independent cultures for each treatment.

**Cell cycle phase distribution**
Cells were seeded at a density of 300,000 cells in 5 ml medium in Petri dishes with 5 cm diameter. They were then incubated for 24 h to allow cell attachment. Then, sideritoflavone was added at 2 or 2.5 μM concentrations. Cells were collected 72 h later by Accutase treatment and resuspended in PBS containing 1% adult bovine serum. The cell concentration was determined by counting in a hemocytometer and a volume corresponding to 0.4 × 10⁶ cells was centrifuged at 600 g for 5 min at 4 °C to pellet the cells. The cells were fixed in 70% ethanol and stored at −20 °C. The fixed cells were washed once with PBS, and after pelleting, the cells were resuspended in propidium iodide (PI)-nuclear isolation medium (PBS containing 100 μg/ml PI (Sigma-Aldrich), 0.6% NP-40 (Sigma-Aldrich), and 100 μg/ml ribonuclease A (Sigma-Aldrich) for at least 30 min at room temperature or overnight at 4 °C. The procedure removes the cell membrane and thus cells in mitosis were not included in the analysis. The method does not allow distinction between G₀ and G₁ phase cells as they have the same DNA content. The samples were analysed using a BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA).

The data were analysed using the MultiCycle software (Phoenix Flow Systems, San Diego, CA, USA).

**CD24/CD44 and ALDH analysis**
The identification of the cell surface markers CD24 and CD44 and the analysis of ALDH positive cells was performed as described by Huang et al. [19]. Sideritoflavone was added to the final concentrations of 2 or 2.5 μM.

**Statistical analysis**
A one-way ANOVA was used to determine if there was a significant difference between control and treatment means, and a Dunnet post-test was used to compare the difference between individual groups and control for all assays. GraphPad Prism version 6.00 for Windows, (GraphPad Software, La Jolla California USA) was used to run all statistical analyses. Treatment groups were considered significantly different if the *p* value was < 0.05.

**Results**

**Dose response experiments**
Dose response experiments were performed treating the cell lines with the three flavones xanthomicrol, xanthomicrol, or sideritoflavone containing differences in the phenyl ring shown in Fig. 1. Among them, only sideritoflavone which has ortho dihydroxy groups (type catechol) in C-3′ and C-4′ showed cytotoxicity at low single digit μM concentrations with an IC₅₀ of 1.9 ± 0.3 μM for JIMT-1 cells (Fig. 2). Treatment with 8-methoxycirsilineol, which has an OMe in C-3′ and an ortho dihydroxy group in C-4′, up to a concentration of 100 μM did not give a cytotoxic effect and treatment with xanthomicrol that only has one OH in C-4′ showed lower cytotoxicity with an IC₅₀ of 99.6 ± 24.1 μM. Sideritoflavone treatment was also toxic to MCF-7 (IC₅₀ 4.9 ± 1.7 μM) and HCC1937 (IC₅₀ 4.6 μM) breast cancer cells and MCF-10A (IC₅₀ 6.7 ± 0.9 μM) normal breast.

Fig. 1 Polymethoxyflavones isolated from *Baccharis densiflora*. 1) 5,4′-dihydroxy-6,7,8,3′-tetramethoxyflavone (8-methoxycirsilineol), 2) 5,4′-dihydroxy-6,7,8-trimethoxyflavone (xanthomicrol), 3) 5,4,3′-trihydroxy-6,7,8-trimethoxyflavone (sideritoflavone)
epithelial cells while methoxycirsilineol and xanthomicrol were much less toxic (IC$_{50}$ $\geq$ 100 $\mu$M) (supplemental information Fig. S1).

Effects on cell proliferation and the cell cycle phase distribution

Since we have used the JIMT-1 cells for intensive investigation of the effect of treating with different compounds on the CSC sub-population, cell movement, and molecular aspects, we decided to use only this cell line for in depth studies [19–24]. In addition, based on the dose response data, we decided to only proceed with sideritoflavone as effects at low doses more easily achievable in the body is important in cancer treatment. We chose to use the doses 2 and 2.5 $\mu$M, the lower dose being close to IC$_{50}$ and a slightly higher dose to get an understanding of the sensitivity to the compound at small differences in treatment concentration.

Figure 3A shows the effect on cell proliferation of treating JIMT-1 cells with 2 or 2.5 $\mu$M sideritoflavone in comparison to control. A slight inhibition of cell proliferation was observed 1 day after addition of the compound and between 2 and 3 days of treatment, the cell number did not change in the treated cultures while control continued to proliferate. At 2 days of treatment, the cell number in cultures treated with 2 and 2.5 $\mu$M sideritoflavone were 73 and 51% of control and at 3 days of treatment, 46 and 33% of control, respectively. Thus, the 2 $\mu$M concentration at 72 h of treatment resulted in an effect on cell number in percent, similar to the IC$_{50}$ obtained from the dose response curve. The MTT data are assumed to reflect cell number which is not always

Fig. 2 Dose response curves obtained after treating JIMT-1 breast cancer cells with A 8-methoxycirsilineol, B xanthomicrol, and C sideritoflavone. The cells were seeded in the wells of 96-well plates and 24 h later the compounds were added at concentrations shown in the figures. The dose response was evaluated with an MTT assay after 72 h of incubation with compound. Each curve shows an independent experiment with mean for n = 6 in each data point. The IC$_{50}$ values were deduced from the MTT-based dose-response curves. The IC$_{50}$ data are presented as the mean ± SD from 2 to 4 experiments.

Fig. 3 Sideritoflavone inhibits cell proliferation and affects cell cycle phase distribution of JIMT-1 breast cancer cells. Cells were seeded day 0, and the compound was added 1 day after seeding to reach the final the concentrations of 2 $\mu$M or 2.5 $\mu$M. Control was treated with 0.1% DMSO which was the same DMSO concentration as in treated cultures. A The cell number was determined using a Holomonitor® M4. Data are presented as the mean of 6 independent samples from 3 independent experiments and bars ± SD. B At 72 h of treatment, cells were sampled for analysis of cell cycle phase distribution using flow cytometry of cells labelled with propidium iodide. The numbers show the cell cycle phase distribution in % for n = 3 ± SD.
the case depending on effects of a compound on the reduction of MTT in mitochondria.

Sideritoflavone treatment resulted in decreased number of cells in the G0/G1 phase while there was an increase in the G2 phase (Fig. 3B).

**Cell movement**

As the ability to migrate is important for cancer cell metastasis, we investigated the effect of sideritoflavone treatment on the migration of the JIMT-1 cells in a wound healing assay using serum free medium to minimise the influence of cell proliferation on the data (Fig. 4). In this assay, the cells move from an edge into a wound area. Sideritoflavone treatment reduced the directed migration of JIMT-1 cells into the wounded area (Fig. 4).

To obtain further details, cell motility was studied in real time using a phase holographic microscope where images were taken every 5 min. The cells were cultured in their regular medium containing FBS in the absence or presence of 2 or 2.5 μM sideritoflavone. Cell motility was evaluated using App Suite™ (Fig. 5). Treatment with sideritoflavone increased the motility of the cells. Motility is defined as the total accumulated distance a cell has moved over the time of tracking. Motility is not a measure of how far the cells are migrating from a starting point but is a measure of how the cells are moving around. Thus, a cell can have low migratory ability but may be moving around in a small spot resulting in high motility. This is the case with JIMT-1 cells treated with sideritoflavone. The time laps movies are found in supplementary information (Time-lapse movie S1, S2, and S3 for control, and 2 and 2.5 μM sideritoflavone, respectively).

**Treatment with sideritoflavone does not affect the cancer stem cell sub-population**

The JIMT-1 breast cancer cell line contains a sub-population of cells with a CSC phenotype defined as CD44+/CD24− and aldehyde dehydrogenase positive (ALDH+) [19–24]. Treatment of JIMT-1 cells with e.g. salinomycin [19, 22, 24] or the sesquiterpene lactones damsin and ambrosin [20] decreases this sub-population as evaluated by determining the effect of treatment on the CD44+/CD24− and aldehyde ALDH+ populations by flow cytometry. When we investigated the effect of sideritoflavone treatment on the CD44+/CD24− and ALDH+ cells, there was no specific reduction of these sub-populations (Fig. 6). CSCs form colonies when seeded at cloning density in serum free medium [25]. In one experiment investigating the effect of sideritoflavone treatment on the colony forming efficiency of JIMT-1 cells, we found no effect on this population (not shown). Thus, we did not repeat the colony forming experiment as the CD44+/CD24− and ALDH+ analyses already showed no effect on the CSCs.

**Signalling pathways affected by sideritoflavone treatment**

We then applied a Cignal Finder Reporter Array (Qiagen) to screen for effects on signal transduction pathways in JIMT-1 cells treated with 2 μM sideritoflavone for 24 h. The data show that treatment with sideritoflavone significantly increased Wnt, Myc/Max, and transforming growth factor-β (TGF-β) signalling (Fig. 7).

![Fig. 4](image-url) Treatment with sideritoflavone reduces cell migration in a wound healing assay. Twenty-four hours after seeding of cells at high density, a wound scratch was made in the cell layer, and after washing, the cells received complete medium without FBS and with the treatment at indicated concentrations. The wound scratch was photographed at 0 h i.e. directly after the scratching and addition of compound, and at 24, 48, and 72 h thereafter. A Quantified wound healing. Data points are the mean of three independent cultures ± SEM. B Representative images. The red lines delineate the initial wound area.
Specific proteins affected by sideritoflavone treatment

Treatment with flavonoids has been reported to increase the p65/NF-κB level [26] as well as decrease p65/NF-κB activity [27]. Here we found that treatment with sideritoflavone increased the cellular level of p65 investigated by Western blot (Fig. 8A).

The increase in Wnt signaling observed in the pathway analysis lead us to investigate the level of β-catenin, however, there was no significant effect on the level as determined by Western blot (Fig. 8B).

Since the DNA histograms indicate DNA damage (broadening of peaks), we decided to investigate γ-H2AX, a marker for DNA double strand breaks [28]. The level of γ-H2AX was increased in cells treated with sideritoflavone compared to control (Fig. 8C). Also, the accumulation of cells in the G2 phase of sideritoflavone-treated cells explains the increased cyclin B1 level (Fig. 8D). Cyclin B1 levels rise in S phase and peak at the G2/M boundary [29].

Discussion

In the present work, we have investigated the toxicity of three methoxy flavones isolated from B. densiflora [7]. The flavones 8-methoxycirsilineol, xanthomicrol, and sideritoflavone have similar structures but very different toxicity profiles in our study. 8-Methoxycirsilineol did not show toxicity up to 100 μM concentration while sideritoflavone was toxic in the single digit μM range. Here we find that sideritoflavone is 50 times more toxic to JIMT-1 cells compared to xanthomicrol despite the fact that the compounds only differ by one hydroxyl group. In sideritoflavone, the phenyl ring contains one catechol fragment and in xanthomicrol the phenyl ring possesses just one OH in C-4’. Grigalius and Petrikaite [30] evaluated seventeen flavones on three different human cancer cell lines, A549 lung cancer cells, the MCF-7 breast cancer cells, and U87 glioblastoma cells. The most active compounds were those with catechols in the phenyl ring which was considered the most important structural feature of flavonoids for antioxidant and anti-
cancer activities [31, 32]. To the best of our knowledge there are no studies comparing the toxicity of the three compounds tested here and overall, there are few studies related to toxicity of these compounds specifically.

Moghaddam et al. [32], compared the cytotoxicity of xanthomicrol with 8 other flavonoids in 6 different cell lines using an MTT assay. For one of the cell lines (human gastric adenocarcinoma) the IC\textsubscript{50} for xanthomicrol was 13 μM while the IC\textsubscript{50} was in the range of 94–161 μM in the other cell lines. Here we found an IC\textsubscript{50} of almost 100 μM for the JIMT-1 cell line and the IC\textsubscript{50} was even higher for the MCF-7 and HCC1937 cell lines. Sideritoflavone was considerably more toxic than xanthomicrol in both the cancer cells (JIMT-1, MCF-7, and HCC1937 with IC\textsubscript{50} of 1.9, 4.9, and 4.6 μM, respectively) and in the normal-like MCF-10A cells (6.7 μM). Comparing IC\textsubscript{50} values of treating JIMT-1 cells and MCF-10A cells with sideritoflavone shows that the former cell line is about 3.5 times more sensitive. To the best of our knowledge, we have only found two studies

![Graph showing the effect of treating JIMT-1 breast cancer cells with sideritoflavone on signal transduction pathways. The Cignal Finder Reporter Array (Qiagen) was used to investigate the effect after 24 h of treatment with 2 μM sideritoflavone. The data show the mean of two experiments compared to control with three independent samples in each ± SEM.](image)

![Graph showing the effect of treatment with sideritoflavone for 72 h on protein levels of p65/NF-κB, β-catenin, γ-H2AX, and cyclin B1. The expression of the proteins was analysed by Western blot after 72 h of treatment at the concentrations shown in the figures. The data were analysed by densitometric scanning and expressed in % of control. n = 3–4 independent experiments ± SEM. The figure includes representative Western blots. The uncropped Western blots are found in Supplementary information Figure S2.](image)
presenting IC₅₀ for sideritoflavone [33, 34]. Novelo et al. [33], report an IC₅₀ of 3 μM in human oralepidermoid carcinoma cells and Beutler et al. [34], an IC₅₀ of 4 μM for the human 60 cell line cytotoxicity screen. Because of these data, we decided to only proceed with further studies treating JIMT-1 breast cancer cells with sideritoflavone.

The IC₅₀ for sideritoflavone obtained using the MTT assay, which is only an indirect determination of cell number was confirmed by an investigation of the effect of sideritoflavone on the cell number through a growth curve experiment. Effects on cell proliferation may result in changes in the cell cycle phase distribution and that is also found for JIMT-1 cells treated with sideritoflavone. The growth inhibitory effect of sideritoflavone was accompanied by an increase in the G₂ phase population and a decrease in the G₁ phase population while the S phase population was almost unchanged. A similar change in cell cycle phase distribution has been found for other cells treated with different flavones [35].

The flavone quercetin has been shown to bind to DNA by intercalation [36]. Intercalation in DNA has been shown to cause DNA double strand breaks [37] and an increased level of γ-H2AX is a biomarker for DNA double strand breaks [28]. Here we found that the level of γ-H2AX increased in sideritoflavone-treated cells compared to control investigated by Western blot. Further studies are needed to confirm DNA double stand breaks, however, that is not within the scope of this research.

The accumulation of cells in G₂ phase caused by sideritoflavone treatment may be a response to induction of DNA double strand breaks. DNA double strand breaks are known to induce a multitude of pathways [38, 39], among which is the c-Myc/Max pathway. The c-Myc/Max pathway was significantly activated in sideritoflavone-treated cells compared to control.

The movement of cells can be described by different terms. Cell motility is regarded as random cell movement, while cell migration is a directed movement due to different signals. Cancer cell migration and invasion may result in the formation of distant metastasis while an increase in cell motility is just a local phenomenon. Here we found that sideritoflavone treatment increased the local motility of JIMT-1 cells, however, directed cell migration evaluated in a wound healing assay was inhibited. Thus, an increased motility does not per se result in increased migration in the wound healing assay. The same has been found when treating JIMT-1 cells with the CSC inhibiting compound salinomycin [40]. Increased cell migration and motility without a clear distinction of the terms have been associated with activation of the TGF-β signaling pathway and with increased p65/NF-κB [41]. Here we did find an activation of the TGF-β signaling pathway and an increased level of p65/NF-κB in sideritoflavone-treated cells with increased motility and decreased migration. Obviously, more studies are needed to understand the connection between motility and migration and the molecular mechanisms involved.

CSCs have been suggested to be the main cause of metastasis and cancer death due to their resistance to treatment and to their ability to migrate [42]. Thus, there is an extensive search for CSC targeting compounds [43, 44]. Treatment with sideritoflavone did not specifically target the CSC population but resulted in a decrease in both the CSC and non-CSC populations to the same degree, as the proportion did not change when the cell number decreased. It may be favourable to combine a specific CSC targeting compound like salinomycin [15] or sesquiterpene lactones [16] with sideritoflavone.

Conclusions
In conclusion, we show here considerable differences in toxicity among the methoxyflavones 8-methoxycirsilineol, xanthomicrol, and sideritoflavone isolated from B. densiflora despite the fact that they have similar chemical structures. Sideritoflavone was markedly more toxic than xanthomicrol while 8-methoxycirsilineol was not toxic up to a 100 μM concentration, showing the importance of a catechol fragment in the phenyl ring of these methoxyflavones. We have not elucidated the exact mechanism by which sideritoflavone inhibits cell proliferation but our data together with reports by others, suggests that DNA intercalation may be the cause for the toxic response. Sideritoflavone treatment inhibited directed cell migration which is a favourable trait for a cancer treatment drug. Sideritoflavone inhibited the non-CSCs and the CSCs to the same extent. Thus, it may be favourable to combine sideritoflavone with CSC targeting compounds.

Abbreviations
ALDH: Aldehyde dehydrogenase; BSA: Bovine serum albumin; CSCs: Cancer stem cells; γ-H2AX: γ-H2A histone family member X; IC₅₀: Inhibitory concentration 50; MTT: 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PHI: Phase holographic imaging; TGF-β: Transforming growth factor-β

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12906-021-03349-4.

Additional file 1: Figure S1. Dose response curves obtained after treating MCF-10A normal-like breast epithelial cells and MCF-7 and HCC1937 breast cancer cells with 8-methoxycirsilineol (only MCF-10 and MCF-7), xanthomicrol, or sideritoflavone. The cells were seeded in 96-well plates and 24 hours later the compounds were added at concentrations shown in the figures. The dose response was evaluated with an MTT assay after 72 hours of incubation with compound. Each curve shows an independent experiment with mean for n = 6 in each data point. The
Acknowledgements
The authors are grateful to the Swedish International Development Agency (SIDA) for the support of this study, which is part of the project “Biomolecules anticancer” developed between the University of San Andres (UMSA, La Paz, Bolivia) and Lund University (Sweden). We also wish to thank the Royal Physiographical Society in Lund, Carolina LePrince with the “Kalenderflickorna”, and associated sponsors. We thank Birgit Janicke and Kersti Alm at PHI for constructive help regarding phase holographic microscopy.

Authors’ contributions
WS and SO conceived and designed the experiments on the basis of compounds provided by GA, and ST. WS performed MTT assays, growth curve experiments, cell cycle analysis, Western blot assays, cell movement, wound healing, and colony forming efficiency experiments. XH, WS, and SO performed the CD44/CD24 assay and the signaling pathways affected by compounds. WS and SO performed the ALDH assays. SO performed the experiments with the H4 holomonitor. SO and WS wrote the paper with important contributions to the content by GA and ST regarding the experiments with the H4 holomonitor. SO and WS wrote the paper with important contributions to the content by GA and ST regarding the chemistry. All authors have approved of the manuscript.

Funding
This work was financially supported by the Research Department of the Swedish International Development Cooperation Agency (SIDA), the Royal Physiological Society in Lund, and Carolina LePrince with the “Kalenderflickorna”, and associated sponsor. Open Access funding provided by Lund University.

Availability of data and materials
All original data are available upon request.

Declarations

Ethics approval and consent to participate
Not applicable since only established cell lines are used.

Consent for publication
All authors consent the publication.

Competing interests
No author has any associations that may represent a potential conflict of interest.

Author details
1Department of Biology, Lund University, Lund, Sweden. 2Molecular Biology and Biotechnology Institute, University Major of San Andres, La Paz, Bolivia. 3Chemical Research Institute, University Major of San Andres, La Paz, Bolivia.

Received: 30 March 2020 Accepted: 8 June 2021
Published online: 02 July 2021

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394–424.
2. Justino G, editor. Flavonoids - From biosynthesis to human health. London: IntechOpen; 2018.
3. Farvid MS, Chen WY, Michels KB, Cho E, Willett WC, Eliassen AH. Fruit and vegetable consumption in adolescence and early adulthood and risk of breast cancer: population based cohort study. BMJ. 2016;353:i1-12.
4. Chen C, Peng W, Tsai K, Hsu S. Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 2007;81(23-24):1602–14. https://doi.org/10.1016/j.lfs.2007.09.028.
5. Walle T, Vincent TS, Walle UK. Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem Pharmacol. 2003;65(10):1603–10. https://doi.org/10.1016/S0006-2952(03)00151-5.
6. Abad MJ, Bessa AL, Ballarin B, Aragón O, Gonzales E, Bermejo P. Anti-inflammatory activity of four Bolivian Baccharis species (Compositae). J Ethnopharmacol. 2006;103(3):338–44. https://doi.org/10.1016/j.jep.2005.08.024.
7. Tanquil ST, Segura YT, Almaraz Vega GR. Polyoxygenated flavonoids from Baccharis penlandii. Rev Boliv Quim. 2012;29:10–4.
8. Martinez MJ, Bessa AL, Benito PB. Biologically active substances from the genus Baccharis L. (Compositae) Atta-ur-Rahman (Ed) Studies in Natural Products Chemistry, vol. 30: Elsevier BV; 2005. p. 703–59.
9. Freire SE, Urtubey E, Giuliano DA. Epidermal characters of Baccharis (Asteraceae) species used in traditional medicine. Caldasia. 2007;29:23–38.
10. Gillet JP, Varma S, Gottesman MA. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105(7):452–8. https://doi.org/10.1093/jnci/djq007.
11. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105–17.
12. Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004;16(6):708–12. https://doi.org/10.1016/j.coeb.2004.09.002.
13. Polyak K. Science in medicine breast cancer: origins and evolution. Cell. 2007;17:3155–63.
14. AH-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8. https://doi.org/10.1073/pnas.0305221100.
15. Ginestet C, Huir MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67. https://doi.org/10.1016/j.stem.2007.08.014.
16. Li ML, Xu LY, Li ZL, Qian MJ. Flavonoids from mentha haplocalyx. J Ethnopharmacol. 2012;30(2):95–101. https://doi.org/10.1016/j.jep.2011.09.049.
17. Jahaniani F, Ebrahimi SA, Rahbar-Roshandel N, Mahmoudian M. Xanthomoricol is the main cytotoxic component of Dracacephalum kotschyi and a potential anti-cancer agent. Phytochemistry. 2005;66(13):1581–91. https://doi.org/10.1016/j.phytochem.2005.04.035.
18. Brahmi Z, Niwa H, Yamamoto M, Shiokato S, Kusakari Y, Sugaya K, et al. Effective cytotoxic chropeptide P450 (CYP) inhibitor isolated from thyme (Thymus sativus) purchased from a Japanese market. Biosci Biotechnol Biochem. 2007;71(1):2237–9. https://doi.org/10.1271/bbb.110532.
19. Huang X, Borgström B, Kemptgren S, Persson L, Hegardt C, Strand D, et al. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomicyn analogs. BMK Cancer. 2016;16(1):11–5. https://doi.org/10.1186/s12958-016-0124-3.
20. Sotillo W, Villagomez R, Smiljanic S, Huang X, Malakpour A, Kempengren S, et al. Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative. PLoS One. 2017;12(9): e0184304. https://doi.org/10.1371/journal.pone.0184304.
21. Huang X, Borgström B, Oredsson SM, Hegardt C, Strand D, et al. Synthetic modification of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified salinomicyn analogues. ACS Chem Biol. 2014;9(7):1587–94. https://doi.org/10.1021/cb502153a.
22. Huang X, Borgström B, Stegmaryr J, Absalys Y, Kruszyn K, Leffler H, et al. The molecular basis for inhibition of stemlike cancer cells by salinomicyn. ACS Cent Sci. 2018;4(6):760–7. https://doi.org/10.1021/acscentsci.8b00257.
23. Tuasha N, Seifu D, Gadisa E, Peters B, Oredsson S. Solvent fractions of selected Ethiopian medicinal plants used in traditional breast cancer treatment inhibit cancer stem cells in a breast cancer cell line. BMC Complement Altern Med. 2020;20(1):366. https://doi.org/10.1186/s12906-020-03154-5.
24. Kamlund S, Janickie B, Alin K, Oredsson S. Salinomicyn treatment specifically inhibits cell proliferation of cancer stem cells revealed by longitudinal single cell tracking in combination with fluorescence microscopy. Appt Sci. 2020;10(14):4732. https://doi.org/10.3390/app10144732.
25. Mather JP. Concise review: Cancer stem cells: in vitro models. Stem Cells. 2012;30(2):95–10. https://doi.org/10.1002/stem.774.
26. von Brandenstein MG, Ngum Abety A, Depping R, Roth T, Koehler M, Dienes HP, et al. A p38-p65 transcription complex induced by endothelin-1...
mediates signal transduction in cancer cells. Biochim Biophys Acta. 1783; 2008:1613–22.

27. Park MH, Hong JE, Park ES, Yoon HS, Seo DW, Hyun BK, et al. Anticancer effect of tectochrysin in colon cancer cell via suppression of NF-kappaB activity and enhancement of death receptor expression. Mcl Cancer. 2015;14:1–12.

28. Kuo LJ, Yang LX. Gamma-H2AX: A novel biomarker for DNA double-strand breaks. In Vivo. 2008;22:305–10.

29. Pines J, Hunter T. Human cyclins a and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol. 1991; 115(1):1–17. https://doi.org/10.1083/jcb.115.1.1.

30. Grigalius I, Petrikaite V. Relationship between antioxidant and anticancer activity of trihydroxyflavones. Molecules. 2017;22(12):2169. https://doi.org/10.3390/molecules22122169.

31. Croft KD. The chemistry and biological effects of flavonoids and phenolic acids. Ann N Y Acad Sci. 1998;854(1 TOWARDS PROLO):435–42. https://doi.org/10.1111/j.1749-6632.1998.tb0922.x.

32. Moghaddam G, Ebrahimi SA, Rahbar-Roshandel N, Foroumadi A. Antiproliferative activity of flavonoids: influence of the sequential methoxylation state of the flavonoid structure. Phyther Res. 2012;26(7):1023–8. https://doi.org/10.1002/ptr.3678.

33. Novelo M, Cruz JG, Hernández L, Pereda-Miranda R, Chai H, Mar W, et al. Cytotoxic constituents from Hyptis verticillata. J Nat Prod. 1993;56(10):1728–36. https://doi.org/10.1021/np50100a011.

34. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727–38. https://doi.org/10.1038/nrc3597.

35. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 1830;2013:3670–95.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions